Oruka Therapeutics, Inc. Common Stock

Oruka Therapeutics' Senior Vice President of Finance Arjun Agarwal sold 9,854 shares worth approximately $687,000 in mid-June 2026, reducing his direct holdings by 36.83%. The sale occurred after the stock had already surged 450% over the previous year and two weeks before it reached nearly 700% gains. The insider sale follows positive Phase 2 cl...

Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, sold 10,290 shares worth approximately $608,000 on May 18, 2026, at a weighted average price of $59.07 per share. The sale was part of a pre-arranged Rule 10b5-1 trading plan and should not concern investors, as it was non-discretionary. The transaction came after the stock su...

Carl Dambkowski, Director of Oruka Therapeutics, sold 105,000 shares worth approximately $6.19 million on May 21, 2026, reducing his direct holdings by 58.74%. Despite the significant sale, Dambkowski retains approximately 73,743 shares and derivative securities. The sale was executed through the exercise and immediate sale of vested options. Oru...

Oruka Therapeutics reported strong phase 2a trial results for ORKA-001, showing 63.5% PASI 100 response rates compared to Skyrizi's typical 51%, potentially threatening AbbVie's $17.6 billion psoriasis drug. However, the article argues AbbVie remains a solid long-term investment due to its diverse pipeline, other growth drivers like Qulipta and B...

Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, generating approximately $700.4 million in gross proceeds. The offering is expected to close on or about April 30, 2026, with underwriters granted a 30-day option to purchase up to 1.45 million additional shares.